Current Oncology Clinical Trials

More people are surviving cancer thanks to research gained through cancer clinical trials. With the collective help of doctors, researchers and cancer patients who choose to participate, cancer clinical trials are able to test the value of the latest research findings of the

National Cancer Institute (NCI).

Rex Cancer Center participates in ongoing cancer clinical trials in collaboration with the University of North Carolina-Chapel Hill. These trials can take several years to complete. They are required by law to include a protocol or action plan for each patient as well as informed consent. In return, knowledge gained from these trials has led to increased survival for many cancers including Hodgkin's disease, certain leukemias, breast, uterine, testicular and bladder cancers.

Cancer knows no boundaries. It touches everyone, whether through personal diagnosis or knowledge of someone with cancer. The statistics are alarming, but the good news is that dramatic improvements have been made in the diagnosis and treatment of cancer as a direct result of invaluable research of cancer clinical trials. The trials open currently at Rex Cancer Center include the following:

Breast Cancer

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy - (also open at the Rex Cancer Center of Wakefield)

SWOG 1207: A Phase III Randomized, Placebo-controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and Her2Neu Negative Breast Cancer (also open at the Rex Cancer Center of Wakefield)

Chronic Phase CML (Chronic Myeloid Leukemia)

Myelodysplastic Syndrome

ECOG 2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response to Treatment with Lenalidomide Alone and in Combination with Epoetin Alfa in Subjects with Low or Intermediate-1 Risk MDS and Asymptomatic Anemia (also open at the Rex Cancer Center of Wakefield)

Pancreatic Cancers

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Prostate Cancer

RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy

RTOG 0815: A Phase III Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

RTOG 0924: A Phase III Randomized Trial of Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer